Why the study?
Does treatment with an anti-CCL5 monoclonal antibody reduce infarct size and post-infarction heart failure in a mouse model of chronic cardiac ischaemia?
Does treatment with an anti-CCL5 monoclonal antibody reduce infarct size and post-infarction heart failure in a mouse model of chronic cardiac ischaemia?
Neutralizing CCL5 reduces infarct size and post-infarction heart failure in mice by decreasing leukocyte recruitment.
No takes yet. Share an insight, caveat, or question.
Anti-CCL5 mAb attenuates post-MI remodeling in mice; hypothesis-generating for human translation, requiring clinical trials.
Montecucco et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: